Puccetti Matteo, Costantini Claudio, Schoubben Aurélie, Giovagnoli Stefano, Ricci Maurizio
Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Front Drug Deliv. 2024 Aug 8;4:1436842. doi: 10.3389/fddev.2024.1436842. eCollection 2024.
This review article explores the potential of engineering antigen-presenting cells (APCs) for the immunotherapy of autoimmune diseases. It discusses various strategies for modifying APCs to induce antigen-specific tolerance, thereby mitigating autoimmune responses. The review covers recent advancements in APC engineering techniques, including genetic modification and nanoparticle-based approaches, and evaluates their efficacy in preclinical models and clinical trials. Additionally, challenges and future directions for the development of APC-based immunotherapies for autoimmunity - and other forms of cell-based immunotherapy - are discussed. Along this direction, this review () describes various strategies for engineering APCs, including genetic modification, nanoparticle delivery systems, and manipulation techniques; () discusses the selection of target antigens and the design of APC-based immunotherapies, and () reviews preclinical models used to evaluate the efficacy and safety of engineered APCs in inducing antigen-specific tolerance.
这篇综述文章探讨了工程化抗原呈递细胞(APC)用于自身免疫性疾病免疫治疗的潜力。文章讨论了多种修饰APC以诱导抗原特异性耐受从而减轻自身免疫反应的策略。综述涵盖了APC工程技术的最新进展,包括基因修饰和基于纳米颗粒的方法,并评估了它们在临床前模型和临床试验中的疗效。此外,还讨论了基于APC的自身免疫性免疫疗法及其他形式的细胞免疫疗法开发面临的挑战和未来方向。沿着这个方向,本综述()描述了工程化APC的各种策略,包括基因修饰、纳米颗粒递送系统和操作技术;()讨论了靶抗原的选择和基于APC的免疫疗法的设计,并且()综述了用于评估工程化APC诱导抗原特异性耐受的疗效和安全性的临床前模型。